Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Presentation ESC 2025

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

Presenter: Faiez Zannad

August 30, 2025

Presentation ESC 2025

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

Presenter: Milind Y Desai

August 30, 2025

Presentation ESC 2025

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Presenter: David D. Berg

August 30, 2025

Presentation ESC 2025

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

Presenter: Borja Ibanez

August 30, 2025

Presentation ESC 2024

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Presenter: Pardeep S. Jhund

September 01, 2024

Presentation ESC 2024

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Presenter: Muthiah Vaduganathan

September 01, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Presentation ESC 2024

Transcatheter versus surgical mitral valve repair in patients with heart failure and secondary mitral regurgitation

Presenter: Volker Rudolph

August 31, 2024

Presentation ESC 2024

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

Presenter: Erwan Donal

August 31, 2024

Presentation ESC 2023

The HEART-FID Trial: Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency

Presenter: Robert Mentz

August 28, 2023

Presentation ESC 2023

Cardiac Resynchronisation Therapy Upgrade in Heart Failure with Right Ventricular Pacing A Multicentre Randomised Controlled Trial

Presenter: Béla Merkely

August 28, 2023

Presentation ESC 2023

The Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial

Presenter: Jozine M. ter Maaten

August 28, 2023

Presentation ESC 2023

DICTATE AHF: Efficacy and Safety of Dapagliflozin in Acute Heart Failure

Presenter: Zachary Cox

August 28, 2023

Presentation ESC 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presenter: Otavio Berwanger

August 29, 2022

Presentation ESC 2022

Percutaneous Revascularisation for Ischaemic Left Ventricular Dysfunction

Presenter: Divaka Perera

August 27, 2022

Presentation ESC 2022

Percutaneous Revascularisation for Ischaemic Left Ventricular Dysfunction

Presenter: Divaka Perera

August 27, 2022

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

Presentation ESC 2016

10-year outcomes of coronary artery bypass grafting vs medical therapy according to age: An update from the STICH trial

Presenter: Eric Velazquez

August 29, 2016

Presentation ESC 2016

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

Presenter: Javed Butler

August 28, 2016

Advertisement

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Transcatheter versus surgical mitral valve repair in patients with heart failure and secondary mitral regurgitation

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

The HEART-FID Trial: Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency

Cardiac Resynchronisation Therapy Upgrade in Heart Failure with Right Ventricular Pacing A Multicentre Randomised Controlled Trial

The Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial

DICTATE AHF: Efficacy and Safety of Dapagliflozin in Acute Heart Failure

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Percutaneous Revascularisation for Ischaemic Left Ventricular Dysfunction

Percutaneous Revascularisation for Ischaemic Left Ventricular Dysfunction

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

10-year outcomes of coronary artery bypass grafting vs medical therapy according to age: An update from the STICH trial

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content